Last reviewed · How we verify
Novel strategy Aspirin
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation. Used for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Mild to moderate pain and fever.
At a glance
| Generic name | Novel strategy Aspirin |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Pain management; Inflammation |
| Phase | FDA-approved |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2, preventing the synthesis of prostaglandins and thromboxane A2. This reduces platelet activation and aggregation, lowering thrombotic risk, while also providing anti-inflammatory and analgesic effects through inhibition of prostaglandin-mediated inflammation.
Approved indications
- Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke)
- Acute coronary syndrome
- Mild to moderate pain and fever
- Inflammatory conditions
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Increased bleeding risk
- Hypersensitivity reactions
Key clinical trials
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (NA)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome (PHASE4)
- Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction (PHASE4)
- Formulation of Compensation Based Intervention (NA)
- LAAO Versus NOAC in Patients with AF and PCI (NA)
- Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novel strategy Aspirin CI brief — competitive landscape report
- Novel strategy Aspirin updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI